The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens
L Duan, Q Zheng, H Zhang, Y Niu, Y Lou… - Frontiers in …, 2020 - frontiersin.org
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a grave threat to global public …
respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a grave threat to global public …
[HTML][HTML] A comprehensive review of the protein subunit vaccines against COVID-19
Two years after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in
December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 …
December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 …
Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
C Keech, G Albert, I Cho, A Robertson… - New england journal …, 2020 - Mass Medical Soc
Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome
coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS …
coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS …
A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
The development of a safe and effective SARS-CoV-2 vaccine is a public health priority. We
designed subunit vaccine candidates using self-assembling ferritin nanoparticles displaying …
designed subunit vaccine candidates using self-assembling ferritin nanoparticles displaying …
[HTML][HTML] Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2
pandemic. We describe the structure-based design of self-assembling protein nanoparticle …
pandemic. We describe the structure-based design of self-assembling protein nanoparticle …
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
SARS-CoV-2 vaccines are advancing into human clinical trials, with emphasis on eliciting
high titres of neutralising antibodies against the viral spike (S). However, the merits of …
high titres of neutralising antibodies against the viral spike (S). However, the merits of …
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
K Lenart, R Arcoverde Cerveira, F Hellgren, S Ols… - npj Vaccines, 2024 - nature.com
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein
vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus …
vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus …
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the
continued development of novel improved formulations capable of reducing the burden of …
continued development of novel improved formulations capable of reducing the burden of …
SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways
Introduction Vaccines are the agreed upon weapon against the COVID-19 pandemic. This
review discusses about COVID-19 subunit vaccines adjuvants and their signaling pathways …
review discusses about COVID-19 subunit vaccines adjuvants and their signaling pathways …
Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice
The COVID-19 pandemic has spurred interest in potent and thermostable SARS-CoV-2
vaccines. Here, we assess low-dose immunization with lyophilized nanoparticles decorated …
vaccines. Here, we assess low-dose immunization with lyophilized nanoparticles decorated …